glp 1 gip dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology Demonstrated metabolic effects of GIP,

The drug was approved in 2019

The synthetic version used in research maintains the same amino acid sequence and biological activity as the naturally occurring fragment

You get better mitochondrial support, protection from free radicals, lower insulin resistance, and improved cellular metabolism

The findings of a study suggest that exploring the potential of Chk1 inhibitors as a targeted therapy may be a promising treatment approach for patients with clear-cell ovarian cancer, presenting a new opportunity for combination therapy (150)

A case-control study (80 NTD-affected pregnancy and 409 controls) in US women found that the lowest concentrations of serum choline ( 399.5 mg/day) were no different than the lowest intakes ( 8.36 M vs